Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
BridgeBio’s Infigratinib Data Reframes Growth Story In Genetic Disorders
BridgeBio Pharma reported positive Phase 3 results for infigratinib in children with achondroplasia, meeting primary and secondary endpoints including improved height velocity and body proportionality. This marks a significant step for the company in genetic skeletal disorders and positions infigratinib as a potential anchor product. BridgeBio plans regulatory submissions in the U.S. and Europe in late 2026 and will accelerate development for related indications.